Skip to main content
Sinopharm Group Co. Ltd. logo

Sinopharm Group Co. Ltd. — Investor Relations & Filings

Ticker · 1099 LEI · 529900N54X78YH9JYK92 HKEX Wholesale and retail trade
Open in API
Filings indexed 1,602 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country CN China
Listing HKEX 1099

About Sinopharm Group Co. Ltd.

http://www.sinopharmholding.com

Sinopharm Group Co. Ltd. is a major state-owned enterprise recognized as the largest pharmaceutical logistics provider in Asia and a leading distributor and retailer of healthcare products. The company's core business revolves around providing comprehensive medical supply chain services, encompassing the wholesale and retail distribution of pharmaceuticals, medical devices, and general healthcare products. Sinopharm serves a broad customer base, including hospitals, primary health service institutions, and retail pharmacies. Furthermore, the Group maintains an integrated ecosystem that extends beyond distribution into the manufacturing of pharmaceuticals and chemical reagents, medical services, and industry-finance integration, positioning it as a full-spectrum service provider in the healthcare sector.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is a routine HKEX Listing Rules monthly return (Form FF301) under Chapter 19B, detailing movements in share capital, issued shares, treasury shares, and public float sufficiency. It is a regulatory filing to the Exchange, not an earnings release, dividend notice, annual or interim report, or other specific disclosure category. It does not merely announce a report or relate to M&A, voting, share issues, or insider dealings. Therefore it falls under the general “Regulatory Filings” category (RNS).
2026-04-09 English
ANNOUNCEMENT PRINCIPAL AUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM ACCORD FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement under Rule 13.09 and Part XIVA disclosing the principal audited accounting data and financial indicators for the year ended 31 December 2025. It provides only high‐level, summary figures (revenue, net profit, EPS, ROE, assets) rather than a full annual report or detailed management discussion. This type of preliminary release of annual financial results matches the description of an Earnings Release (ER). It is not the full Annual Report (10-K), a Report Publication Announcement (which would only state that a report is available), nor any other specific category. FY 2025
2026-04-01 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 1% confidence The document is extremely short and simply notes that an issuer’s announcement has been published elsewhere (in the Chinese section of the website). It does not contain substantive report content, financial data, or detailed notice. This matches a Report Publication Announcement (RPA).
2026-04-01 English
PROPOSED DISTRIBUTION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS
Notice of Dividend Amount Classification · 1% confidence The document is a Hong Kong EXchange announcement entitled “Cash Dividend Announcement for Equity Issuer” for Sinopharm Group Co. Ltd., detailing the final dividend per share, dividend dates (ex-dividend, record, payment), withholding tax rates, and register closure. This fits the definition of “Notice of Dividend Amount” as it announces the dividend amount, payment date, and related shareholder details.
2026-03-22 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is a full text “Annual Results Announcement for the Year Ended 31 December 2025” published by Sinopharm Group on the Hong Kong Exchange, containing the Chairman’s statement and detailed management commentary of the year‐end financial performance. It is not the full statutory annual report (10-K) but an initial published set of annual results (akin to a press release of full‐year earnings). This aligns with the definition of an Earnings Release (ER). FY 2025
2026-03-22 English
ANNOUNCEMENT PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is an announcement from Sinopharm Group Co. Ltd. regarding the principal accounting data and financial indicators of its subsidiary, China National Medicines Corporation Ltd. (CNCM), for the year ended 31 December 2025. While it contains financial tables, it is structured as a formal regulatory announcement (as indicated by the 'ANNOUNCEMENT' header and the 'By order of the Board' sign-off) rather than a full annual report or a standalone earnings release of the parent company. Given it provides key financial highlights of a subsidiary to shareholders, it fits best under the 'Regulatory Filings' category as a general corporate disclosure. FY 2025
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.